Categories | Inventors

Oligonucleotides for Long QT Syndrome


OHSU # 2044

Technology Overview:

Oligonucleotides to prevent poly(A) adenylation at intron 9 of the KCNH2 gene, and pharmaceutical compositions comprising the oligonucleotides and methods to use same to treat long QT syndrome. Included are antisense sequences to specific sites in intron 9.

KCNH2, also known as ether-a-go-go related gene 1 (hERG1) encodes the Kv11.1 channel that conducts the rapidly activating delayed rectifier K+ current in the heart. These channels are essential for cardiac action potential repolarization. Mutations in KCNH2 cause long QT syndrome type 2 (LQT2). The OHSU oligonucleotides are morpholino oligonucleotides which can be used to treat long-QT syndrome caused by mutations in the KCNH2 gene.

US Non-Provisional and PCT patent application filed 01/20/2015.

US Patent 9,434,947 issued Sept. 06, 2016.



PublishedPatent Cooperation TreatyWO 2016/118118
IssuedUnited States9,434,947
IssuedUnited States9,957,508


For more information, contact:

Michele Gunness
Senior Technology Development Manager